Shanghai Hile Bio-tech (603718) - Net Assets
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) has net assets worth CN¥971.57 Million CNY (≈ $142.17 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.38 Billion ≈ $201.87 Million USD) and total liabilities (CN¥408.00 Million ≈ $59.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shanghai Hile Bio-tech strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥971.57 Million |
| % of Total Assets | 70.43% |
| Annual Growth Rate | 5.82% |
| 5-Year Change | -9.24% |
| 10-Year Change | -10.88% |
| Growth Volatility | 25.53 |
Shanghai Hile Bio-tech - Net Assets Trend (2011–2025)
This chart illustrates how Shanghai Hile Bio-tech's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Shanghai Hile Bio-tech market capitalisation.
Annual Net Assets for Shanghai Hile Bio-tech (2011–2025)
The table below shows the annual net assets of Shanghai Hile Bio-tech from 2011 to 2025. Also explore 603718 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥895.97 Million ≈ $131.11 Million |
-47.39% |
| 2024-12-31 | CN¥1.70 Billion ≈ $249.23 Million |
+44.98% |
| 2023-12-31 | CN¥1.17 Billion ≈ $171.91 Million |
+5.74% |
| 2022-12-31 | CN¥1.11 Billion ≈ $162.57 Million |
+12.54% |
| 2021-12-31 | CN¥987.19 Million ≈ $144.46 Million |
+2.60% |
| 2020-12-31 | CN¥962.20 Million ≈ $140.80 Million |
-3.06% |
| 2019-12-31 | CN¥992.57 Million ≈ $145.24 Million |
-3.24% |
| 2018-12-31 | CN¥1.03 Billion ≈ $150.10 Million |
-4.57% |
| 2017-12-31 | CN¥1.07 Billion ≈ $157.29 Million |
+6.92% |
| 2016-12-31 | CN¥1.01 Billion ≈ $147.11 Million |
+4.36% |
| 2015-12-31 | CN¥963.31 Million ≈ $140.96 Million |
+72.48% |
| 2014-12-31 | CN¥558.50 Million ≈ $81.73 Million |
+11.55% |
| 2013-12-31 | CN¥500.66 Million ≈ $73.26 Million |
+7.01% |
| 2012-12-31 | CN¥467.89 Million ≈ $68.47 Million |
+15.32% |
| 2011-12-31 | CN¥405.74 Million ≈ $59.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Hile Bio-tech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥28.29 Million | 3.21% |
| Other Components | CN¥853.75 Million | 96.79% |
| Total Equity | CN¥882.04 Million | 100.00% |
Shanghai Hile Bio-tech Competitors by Market Cap
The table below lists competitors of Shanghai Hile Bio-tech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stove Kraft Limited
NSE:STOVEKRAFT
|
$291.59 Million |
|
Fabryka Farb i Lakierów ŚNIEŻKA SA
WAR:SKA
|
$291.70 Million |
|
Jouder Precision Industry Kunshan Co Ltd
SHE:300549
|
$291.70 Million |
|
Profit Cultural & Creative Group Co Ltd
SHE:300640
|
$291.71 Million |
|
Pan Malaysia Holdings Bhd
KLSE:1287
|
$291.51 Million |
|
Text S.A.
WAR:TXT
|
$291.41 Million |
|
Dongsung FineTec Co. Ltd
KQ:033500
|
$291.30 Million |
|
Taiga Building Products Ltd.
TO:TBL
|
$291.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Hile Bio-tech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,560,478,382 to 882,040,945, a change of -678,437,437 (-43.5%).
- Net loss of 311,436,623 reduced equity.
- Dividend payments of 122,262,311 reduced retained earnings.
- Other factors decreased equity by 244,738,504.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-311.44 Million | -35.31% |
| Dividends Paid | CN¥122.26 Million | -13.86% |
| Other Changes | CN¥-244.74 Million | -27.75% |
| Total Change | CN¥- | -43.48% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Hile Bio-tech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.06x to 2.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.76 | CN¥3.07 | x |
| 2012-12-31 | CN¥0.97 | CN¥3.07 | x |
| 2013-12-31 | CN¥1.01 | CN¥3.07 | x |
| 2014-12-31 | CN¥1.13 | CN¥3.07 | x |
| 2015-12-31 | CN¥1.65 | CN¥3.07 | x |
| 2016-12-31 | CN¥1.49 | CN¥3.07 | x |
| 2017-12-31 | CN¥1.66 | CN¥3.07 | x |
| 2018-12-31 | CN¥1.64 | CN¥3.07 | x |
| 2019-12-31 | CN¥1.75 | CN¥3.07 | x |
| 2020-12-31 | CN¥1.19 | CN¥3.07 | x |
| 2021-12-31 | CN¥1.49 | CN¥3.07 | x |
| 2022-12-31 | CN¥1.78 | CN¥3.07 | x |
| 2023-12-31 | CN¥1.94 | CN¥3.07 | x |
| 2024-12-31 | CN¥2.37 | CN¥3.07 | x |
| 2025-12-31 | CN¥1.35 | CN¥3.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Hile Bio-tech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -165.77%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.28x
- Recent ROE (-35.31%) is below the historical average (8.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 26.44% | 41.24% | 0.52x | 1.24x | CN¥66.70 Million |
| 2012 | 24.05% | 36.21% | 0.55x | 1.20x | CN¥65.76 Million |
| 2013 | 24.34% | 37.26% | 0.53x | 1.23x | CN¥69.99 Million |
| 2014 | 18.50% | 35.48% | 0.44x | 1.20x | CN¥46.50 Million |
| 2015 | 10.32% | 30.14% | 0.26x | 1.34x | CN¥3.00 Million |
| 2016 | 8.71% | 24.91% | 0.23x | 1.51x | CN¥-12.62 Million |
| 2017 | 10.63% | 37.46% | 0.19x | 1.50x | CN¥6.78 Million |
| 2018 | 2.02% | 8.37% | 0.15x | 1.66x | CN¥-84.25 Million |
| 2019 | 1.15% | 4.37% | 0.16x | 1.60x | CN¥-93.93 Million |
| 2020 | 0.84% | 3.44% | 0.15x | 1.69x | CN¥-96.91 Million |
| 2021 | 5.36% | 15.51% | 0.19x | 1.83x | CN¥-46.70 Million |
| 2022 | 10.66% | 40.54% | 0.20x | 1.33x | CN¥7.57 Million |
| 2023 | 5.17% | 26.12% | 0.15x | 1.36x | CN¥-58.83 Million |
| 2024 | 10.97% | 63.16% | 0.15x | 1.17x | CN¥15.13 Million |
| 2025 | -35.31% | -165.77% | 0.17x | 1.28x | CN¥-399.64 Million |
Industry Comparison
This section compares Shanghai Hile Bio-tech's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,212,454,258
- Average return on equity (ROE) among peers: 6.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Hile Bio-tech (603718) | CN¥971.57 Million | 26.44% | 0.42x | $291.55 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $128.42 Million | 3.01% | 0.85x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $56.30 Million | 0.00% | 2.39x | $1.38 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $423.50 Million | 7.52% | 0.41x | $663.06 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $208.96 Million | -6.84% | 0.25x | $552.91 Million |
| Chengzhi Shareholding Co Ltd (000990) | $975.70 Million | 5.10% | 0.96x | $1.58 Billion |
| Hualan Biological EngineeringInc (002007) | $588.30 Million | 13.43% | 0.39x | $3.51 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.64 Billion | 3.27% | 0.76x | $1.16 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $754.76 Million | 13.88% | 0.10x | $4.84 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.23 Billion | 6.74% | 0.25x | $470.40 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $4.11 Billion | 14.16% | 0.65x | $1.62 Billion |
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The company offers biochemistry reagents, immunoturbidimetric latex reagents, immune turbidimetry reagents, latex enhanced … Read more